目的 探討元胡止痛膠囊聯(lián)合鹽酸洛美利嗪膠囊治療偏頭痛的療效。方法 選取河北醫(yī)科大學(xué)第三醫(yī)院在2022年9月—2024年9月收治的偏頭痛患者共計(jì)120例，按隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組60例。對(duì)照組患者口服鹽酸洛美利嗪膠囊，2次/d，1粒/次。治療組患者在對(duì)照組治療的基礎(chǔ)上口服元胡止痛膠囊，3次/d，2粒/次。兩組患者均持續(xù)治療1個(gè)月。對(duì)比兩組的治療效果、偏頭痛癥狀、生活質(zhì)量、腦部血流動(dòng)力學(xué)、血清指標(biāo)。結(jié)果 治療后，治療組的總有效率95.00%明顯高于對(duì)照組的總有效率81.67%，組間差異顯著（P＜0.05）。兩組治療后的發(fā)作頻次、持續(xù)時(shí)間、視覺(jué)模擬量表（VAS）評(píng)分均顯著降低（P＜0.05）；治療組治療后發(fā)作頻次、持續(xù)時(shí)間、VAS評(píng)分均低于對(duì)照組（P＜0.05）。治療后，兩組的偏頭痛生活質(zhì)量問(wèn)卷（MSQ）評(píng)分顯著減?。?i>P＜0.05），且治療組的MSQ評(píng)分小于對(duì)照組（P＜0.05）。兩組治療后的腦中動(dòng)脈收縮期峰值速度（Vs）、阻力指數(shù)（RI）、搏動(dòng)指數(shù)（PI）均降低（P＜0.05），且治療組的腦中動(dòng)脈Vs、RI、PI低于對(duì)照組（P＜0.05）。兩組治療后的血清降鈣素基因相關(guān)肽（CGRP）、環(huán)氧合酶-2（COX-2）、基質(zhì)金屬蛋白酶-9（MMP-9）水平均降低（P＜0.05）；治療組治療后血清CGRP、COX-2、MMP-9水平低于對(duì)照組（P＜0.05）。結(jié)論 元胡止痛膠囊聯(lián)合鹽酸洛美利嗪膠囊可提高偏頭痛的臨床療效，明顯減輕偏頭痛癥狀，提高患者生活質(zhì)量，改善腦部血流動(dòng)力學(xué)水平，減輕炎癥反應(yīng)。

Objective To explore the efficacy of Yuanhu Zhitong Capsules combined with Lomerizine Hydrochloride Capsules in treatment of migraine. Methods A total of 120 patients admitted to Hebei Medical University Third Hospital from September 2022 to September 2024 were selected, and all patients were randomly divided into control group and treatment group using a random number table method, with 60 patients in each group. Patients in the control group took Lomerizine Hydrochloride Capsules orally, twice daily, 1 capsule/time. Patients in the treatment group took Yuanhu Zhitong Capsules orally on the basis of the control group, 3 times daily, 2 capsules/time. Two groups of patients received continuous treatment for one month. The clinical efficacy, migraine symptoms, quality of life, cerebral hemodynamics, and serum indicators were compared between the two groups. Results After treatment, the total effective rate of the treatment group (95.00%) was significantly higher than 81.67% of the control group, and the difference between the two groups was significant (P < 0.05). After treatment, the frequency, duration, and VAS scores in both groups were significantly decreased (P < 0.05), and the frequency, duration, and VAS scores in the treatment group was lower than that in the control group (P < 0.05). After treatment, the MSQ scores of both groups were significantly decreased (P < 0.05), and the MSQ scores in the treatment group was more obvious lower than those in the control group (P < 0.05). The Vs, RI, and PI of the middle cerebral artery in both groups after treatment were decreased (P < 0.05), and the Vs, RI, and PI of the middle cerebral artery in the treatment group was lower than that in the control group (P < 0.05). The serum levels of CGRP, COX-2, and MMP-9 in both groups after treatment were significantly decreased (P < 0.05). After treatment, the serum levels of CGRP, COX-2 and MMP-9 in the treatment group were lower than those in the control group (P < 0.05). Conclusion: Yuanhuzhitong Capsules combined with Lomerizine Hydrochloride Capsules can improve the efficacy of migraine, significantly relieve migraine symptoms, improve the quality of life of patients, improve cerebral hemodynamics, and reduce inflammatory response.

R971

河北省衛(wèi)生健康委醫(yī)學(xué)科學(xué)研究課題計(jì)劃（20190082）